Comparative Pharmacology
Head-to-head clinical analysis: EC NAPROSYN versus TOLMETIN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EC NAPROSYN versus TOLMETIN SODIUM.
EC-NAPROSYN vs TOLMETIN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis. It has anti-inflammatory, analgesic, and antipyretic effects.
500-1000 mg orally twice daily; maximum 1500 mg/day.
400 mg orally three times daily; maximum 1800 mg/day.
None Documented
None Documented
Terminal elimination half-life 12-17 hours (mean 14 hours); prolonged in elderly and renal impairment
Terminal elimination half-life is approximately 4.5–6 hours (mean 5 hours); may be prolonged in elderly or patients with renal impairment
Renal (95%) as unchanged drug (10%) and conjugated metabolites (60%) and other metabolites (25%); biliary/fecal (5%)
Renal excretion (~90% as unchanged drug and conjugates), with fecal excretion (~10% as metabolites)
Category C
Category D/X
NSAID
NSAID